Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLUTREPRO: Dapagliflozin in CKD
NCT05998837Phase 3Completed
- Start
- Apr 2021
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dapagliflozin in chronic kidney disease (CKD) (4 arms). Primary endpoints: Urinary proximal tubule cells changes in protein expression of inflammatory genes at 18 months, Urinary proximal tubule cells changes in fibrosis-related genes at 18 months and 1 more. Started Apr 2021; status: completed.
02
Drugs
dapagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT05998837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05998837.